# AxoGen (AXGN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/AXGN
## Company Profile
- Ticker: AXGN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 49.67 USD
- Market cap: 2098396935.04 USD
- Last updated: 2026-08-12
## Business Overview
### Peripheral Nerve Repair Specialist
Axogen is a commercial-stage medical technology company focused on peripheral nerve regeneration and repair. Its products are used by surgeons to help restore nerve function after traumatic injuries or surgical procedures that damage motor or sensory nerves.
### Core Surgical Product Portfolio
The company's portfolio includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. These products form a focused toolkit for nerve grafting, nerve protection, neuroma management, and soft tissue support.
### Target Procedure Markets
Axogen's growth is concentrated across Extremities, Oral Maxillofacial and Head and Neck, and Breast. Management highlighted broad-based growth through the second quarter of 2026, supported by account productivity, expanding sales force coverage, and improving commercial insurance coverage and payment.
### Evidence and Adoption Strategy
Axogen is investing in Level 1 evidence to support broader adoption. REPOSE evaluated Axoguard Nerve Cap for symptomatic neuroma management, while Nerve-RESTORE is comparing Avance Nerve Graft with sural nerve autograft in mixed and motor nerve reconstruction.
## Why The Stock Is Moving

As of Aug 12, 2026, AXGN closed up 2.45% at $49.67. No new same-company headline was identified in the current news window.

## Future Catalysts

- Future evidence from the Nerve-RESTORE randomized study comparing Avance Nerve Graft with sural nerve autograft in mixed and motor nerve reconstruction.

## Recent News
- 2026-07-29 11:05 EST — [Axogen, Inc. Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/AXGN/axogen-inc-reports-second-quarter-2026-financial-results-4cea3351) — Source: AxoGen
- 2026-07-15 11:00 EST — [Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026](https://biopharmsignal.com/news/AXGN/axogen-inc-to-report-second-quarter-2026-financial-results-on-july-29-2026-56aa71ab) — Source: AxoGen
- 2026-04-30 11:00 EST — [Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference](https://biopharmsignal.com/news/AXGN/axogen-inc-to-participate-in-the-2026-bank-of-america-global-healthcare-conference) — Source: AxoGen
- 2026-04-28 11:00 EST — [Axogen, Inc. Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/AXGN/axogen-inc-reports-first-quarter-2026-financial-results) — Source: AxoGen
- 2026-04-14 11:00 EST — [Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026](https://biopharmsignal.com/news/AXGN/axogen-inc-to-report-first-quarter-2026-financial-results-on-april-28-2026) — Source: AxoGen